2023
An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma
Barkhoudarian G, Badruddoja M, Blondin N, Chowdhary S, Cobbs C, Duic J, Flores J, Fonkem E, McClay E, Nabors L, Salacz M, Taylor L, Vaillant B, Gill J, Kesari S. An expanded safety/feasibility study of the EMulate Therapeutics Voyager™ System in patients with recurrent glioblastoma. CNS Oncology 2023, 12: cns102. PMID: 37462385, PMCID: PMC10410686, DOI: 10.2217/cns-2022-0016.Peer-Reviewed Original ResearchMeSH KeywordsBrain NeoplasmsFeasibility StudiesGlioblastomaHumansNeoplasm Recurrence, LocalProspective StudiesConceptsMedian overall survivalProgression-free survivalOverall survivalRecurrent glioblastomaAdverse eventsTherapy groupMedian progression-free survivalDevice-related adverse eventsSafety/feasibilitySerious adverse eventsFurther prospective studiesConcurrent therapyInvestigator's discretionStandard chemotherapyProspective studyTRIAL REGISTRATIONPatientsMonthsTreatmentHome-use deviceGlioblastomaWeeksSurvivalTotalGroup
2010
Thrombolysis in Right versus Left Hemispheric Stroke
Blondin NA, Staff I, Lee N, McCullough LD. Thrombolysis in Right versus Left Hemispheric Stroke. Journal Of Stroke And Cerebrovascular Diseases 2010, 19: 269-272. PMID: 20471856, DOI: 10.1016/j.jstrokecerebrovasdis.2009.04.012.Peer-Reviewed Original ResearchConceptsLeft hemispheric strokeRight hemispheric strokeT-PA administrationHemispheric strokeAcute strokeStroke centersEmergency departmentT-PAIntravenous recombinant tissue plasminogen activatorRecombinant tissue plasminogen activatorLarge community populationLarge prospective cohortPoor clinical outcomeT-PA useRight hemispheric syndromeTissue plasminogen activatorAffected hemisphereIschemic strokeProspective cohortClinical outcomesHemispheric syndromeStudy inclusionStudy populationPatientsStroke